ZLAB: Zai Lab Ltd Company Value to Net Income

Zai Lab Ltd - graphic logo of issuer ZLAB

Zai Lab Limited (ZLAB) generates revenue by commercializing advanced medications from global partners for Chinese patients with severe pathologies. The current price-to-earnings ratio reflects the market valuation of the business, where the value -15.30 describes the current cost level. Efficiency is increasing through the integration of AI into research analysis, while a substantial cash reserve offsets temporary liquidity shortages during the launch of new products.

Zai Lab Ltd. (ZLAB) - Price to Earnings Ratio from 07/04/2022 to 11/10/2026

Comprehensive metric breakdowns and analytics for Zai Lab Ltd. (ZLAB)

- price and consensus price forecast:
Stock Price zailaboratory.com|ZLAB - Consensus Target
- market capitalization information:
Market Value Zai Lab Limited|ZLAB - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Zai Lab|ZLAB - Company Book Value|Market-to-Book Ratio zailaboratory.com|ZLAB - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Zai Lab Limited|ZLAB - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Zai Lab Corp|ZLAB - Company Aggregate Debts|Debts to Net Assets Zai Lab Limited|ZLAB - Company Long-Term Debt|Company Short-Term Indebtedness Zai Lab|Critical Liquidity zailaboratory.com
- earnings and valuation multiples indicators:
ZLAB - Net Income|Forward Earnings Zai Lab Limited|ZLAB - P/E Multiple|Forward P/E Multiple Zai Lab Ltd|ZLAB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Zai Lab Limited|ZLAB - Operating profit before deduction of amortization|Earnings per share for the trailing year Zai Lab|ZLAB - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months zailaboratory.com|ZLAB - Earnings growth in current year|Earnings growth forecast for next year Zai Lab Limited
Summary company analysis:Zai Lab Limited
Brand item of zailaboratory.com

Investors verify business resilience through the market capitalization to net income ratio, determining the cost of one dollar of current earnings. By analyzing the historical P/E dynamics of Zai Lab Limited (ZLAB), one can assess how inelastic demand for oncology drugs and the licensing strategy in China support high asset valuations for Zai Lab Limited (ZLAB) relative to generated cash flow.

Analysis of competing companies

P/E Multiple lilly.com|Price to Earnings Ratio ABBV (AbbVie)|AZN (AstraZeneca Plc) - Company Value to Net Income|P/E Multiple NVS (Novartis Inc.)|Company Value to Net Income MRK|NVO - Price to Earnings Ratio|Market Cap to Earnings amgen.com|Pfizer (PFE) - Price to Earnings Ratio|SNY (Sanofi SA) - Price to Earnings Ratio|BMY (BMS) - P/E Multiple|Price to Earnings Multiple GSK (GSK Corp)|P/E Multiple TAK|Business Payback Period Teva Pharmaceuticals|Price to Earnings Ratio Dr. Reddy's RDY|VTRS: Price to Earnings Multiple|Roivant Sciences Ltd - P/E Multiple|Market Cap to Net Income Ratio Bausch Health Corp (BHC)|COSM (Cosmos Health Inc.) - Price to Earnings Ratio